文献速递肝病

特利加压素治疗203例肝肾综合征患者的真实世界治疗模式与结局

Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-04

英国26家医院2013年1月至2017年12月多中心病历回顾,225例肝肾综合征患者中203例(90%)接受特利加压素治疗,中位疗程6天。特利加压素总体应答率73%,轻度急性肾损伤(基线血肌酐<2.25 mg/dL)患者应答率高于中度和重度患者;90天生存率86%,应答者93% vs 无应答者66%(P<0.0001)。

要点

  • 特利加压素是英国医院肝肾综合征最常用的血管收缩剂,203/225例(90%)使用。
  • 特利加压素总体应答率73%,轻度急性肾损伤患者应答率更高。
  • 90天生存率86%,应答者93% vs 无应答者66%(P<0.0001)。

核心结论

  • 特利加压素是英国肝肾综合征患者最常用的血管收缩剂;较轻急性肾损伤(血肌酐<2.25 mg/dL)患者治疗应答率和90天生存率更高。

研究设计与样本

  • 多中心病历回顾研究,纳入英国26家医院2013年1月至2017年12月诊断肝肾综合征并接受血管收缩剂治疗的患者,共225例纳入分析,其中203例(90%)使用特利加压素。

主要发现

  • 特利加压素中位疗程6天(范围2-24天),起始血管加压时平均血肌酐3.25±1.64 mg/dL。
  • 特利加压素总体应答率73%,轻度急性肾损伤(基线血肌酐<2.25 mg/dL)患者应答率高于中度(≥2.25且<3.5 mg/dL)或重度(≥3.5 mg/dL)患者。
  • 90天生存率全部患者为86%,总体应答者93% vs 治疗无应答者66%(P<0.0001)。

临床怎么用

  • 原文结论指出,对较轻急性肾损伤(血肌酐<2.25 mg/dL)患者使用特利加压素与更高的治疗应答率和90天生存率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatorenal syndrome and acute kidney injury are common complications of decompensated cirrhosis, and terlipressin is recommended as first-line vasoconstrictor therapy. However, data on its use outside of clinical trials are lacking. AIMS: To assess practice patterns and outcomes around vasoconstrictor use for hepatorenal syndrome in UK hospitals. METHODS: This was a multicentre chart review study. Data were extracted from medical records of patients diagnosed with hepatorenal syndrome and treated by vasoconstrictor drugs between January 2013 and December 2017 at 26 hospitals in the United Kingdom. The primary outcome was improvement of kidney function, defined as complete response (serum creatinine improved to ≤1.5 mg/dL), partial response (serum creatinine reduction of ≥20% but >1.5 mg/dL) and overall response (complete or partial response). Other outcomes included need for dialysis, mortality, liver transplantation and adverse events. RESULTS: Of the 225 patients included in the analysis, 203 (90%) were treated with terlipressin (median duration, 6 days; range: 2-24 days). Mean (±standard deviation) serum creatinine at vasopressor initiation was 3.25 ± 1.64 mg/dL. Terlipressin overall response rate was 73%. Overall response was higher in patients with mild acute kidney injury (baseline serum creatinine <2.25 mg/dL), compared to those with moderate (serum creatinine ≥2.25 mg/dL and <3.5 mg/dL) or severe (serum creatinine ≥3.5 mg/dL). Ninety-day survival was 86% for all patients (93% for overall responders vs 66% for treatment nonresponders, P < 0.0001). CONCLUSION: Terlipressin is the most commonly prescribed vasoconstrictor for patients with hepatorenal syndrome in the United Kingdom. Treatment with terlipressin in patients with less severe acute kidney injury (serum creatinine <2.25 mg/dL) was associated with higher treatment responses, and 90-day survival.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Moore K, Jamil K, Verleger K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2020. PMID: 32495956. doi:10.1111/apt.15836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。